A Randomized Trial of Ustekinumab, a Human Interleukin-12/23 Monoclonal Antibody, in Patients With Moderate-to-Severe Crohn's Disease Academic Article uri icon

Overview

MeSH Major

  • Antibodies, Monoclonal
  • Crohn Disease
  • Immunosuppressive Agents
  • Interleukin-12
  • Interleukin-23

abstract

  • Ustekinumab induced a clinical response in patients with moderate-to-severe Crohn's disease, especially in patients previously given infliximab.

publication date

  • October 2008

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1053/j.gastro.2008.07.014

PubMed ID

  • 18706417

Additional Document Info

start page

  • 1130

end page

  • 41

volume

  • 135

number

  • 4